To the full analysis
Ionis Pharmaceuticals stock: growth
IONSIonis Pharmaceuticals reported $944M in revenue for fiscal 2025, up 33.9% on the prior year, up 5.3% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
24.4%
per year from 2006 to 2025, per share 19.5%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 5.3% | 12.8% | 24.4% |
| Revenue per share | 2.5% | 9.5% | 19.5% |
| Earnings | no data | no data | no data |
| Earnings per share | no data | no data | no data |
| Free cash flow | no data | no data | no data |
| Free cash flow per share | no data | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $14.86M | −$45.9M | −$55.78M |
| 2007 | $58.34M | −$10.99M | $31.08M |
| 2008 | $107.19M | −$18.17M | $194.96M |
| 2009 | $121.6M | $155.07M | −$124.74M |
| 2010 | $108.47M | −$61.25M | −$81.15M |
| 2011 | $99.09M | −$84.8M | −$125.8M |
| 2012 | $102.05M | −$65.48M | −$3.29M |
| 2013 | $147.29M | −$60.64M | $58.13M |
| 2014 | $214.16M | −$38.98M | −$4.82M |
| 2015 | $283.7M | −$88.28M | $9.38M |
| 2016 | $372.78M | −$60.4M | −$123.63M |
| 2017 | $514.18M | $346K | $136.29M |
| 2018 | $599.67M | $273.74M | $585.24M |
| 2019 | $1.12B | $278.14M | $309.44M |
| 2020 | $729.26M | −$444.26M | −$5.16M |
| 2021 | $810.46M | −$28.6M | $12.9M |
| 2022 | $587.37M | −$269.72M | −$294.47M |
| 2023 | $787.65M | −$366.29M | −$335.52M |
| 2024 | $705.14M | −$453.9M | −$546.23M |
| 2025 | $944M | −$381M | −$320.03M |
Revenue by segment
How Ionis Pharmaceuticals, Inc. makes its money and how that has shifted. Names are as the company reports them.
- Commercial Member$435.8M46%
- Royalty$285.5M30%
- Product$115.3M12%
- Other$107.3M11%
“Other” combines smaller and former segments with revenue the company does not assign to a segment. Names as reported, with abbreviations spelled out for the largest companies. The company split earlier years differently. A history would not be comparable, so only 2025 is shown.
Figures as a table
| 2025 | Share 2025 | |
|---|---|---|
| Commercial Member | $435.85M | 46.2% |
| Royalty | $285.53M | 30.2% |
| Product | $115.32M | 12.2% |
| Other | $107.31M | 11.4% |
| Total revenue | $944M | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 28 Feb 2021)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.